This is an excerpt from a 1,340-word article in the January 9 issue of THE DARK REPORT. The complete article is available for a limited time to all readers, and available at all times to paid members of the Dark Intelligence Group. CEO SUMMARY: Pharmacogenomic testing is expected to be a linchpin to the practice of […]
Pharmacogenomic Testing Draws $26 Million Recoupment from Medicare Audit
Repayment demand to pharmacogenomic testing lab could be a sign that federal payers can't afford PGX
- By Mary Van Doren
- > From the Volume XXIV No. 1 - January 9, 2017 Issue
- Tags: aco, cap, clinical lab, clinical labs, dark intelligence, dark intelligence group, dark report, diagnostic lab, diagnostic laboratories, diagnostic laboratory, diagnostic testing, exome sequencing, genomic testing, genomics, informatics, lab executive, lab industry, lab test, laboratories, laboratory medicine, medical records, Medicare, Medicare Administrative Contractor, Medicare Part B, molecular diagnostic, molecular diagnostic test, molecular diagnostic testing, pathologists, Pathology group, pathology groups, patient record, pgxl, pgxl bankruptcy, pharmacogenetic, pharmacogenetics, pharmacogenetics diagnostic laboratory, pharmacogenomic tests, pharmacogenomics, private payer, the dark intelligence group, the dark report
